Epidermal growth factor receptor in asthma: A promising therapeutic target?

Ye Liu; Pengfei Li; Tianci Jiang; Yue Li; Yu Wang; Zhe Cheng

doi:10.1016/j.rmed.2023.107117

Epidermal growth factor receptor in asthma: A promising therapeutic target?

Respir Med. 2023 Feb:207:107117. doi: 10.1016/j.rmed.2023.107117. Epub 2023 Jan 7.

Authors

Ye Liu¹, Pengfei Li¹, Tianci Jiang¹, Yue Li¹, Yu Wang², Zhe Cheng³

Affiliations

¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
² Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: yuwang_westchina@163.com.
³ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: fccchengzhe@zzu.edu.cn.

PMID: 36626942
DOI: 10.1016/j.rmed.2023.107117

Abstract

Activation of the epidermal growth factor receptor (EGFR) pathway is involved in the pathogenesis of asthma. Although decades of intensive research have focused on the role of EGFR in asthma, the specific mechanisms and pathways of EGFR signaling remain unclear. Various reports have indicated that inhibition of EGFR improves the pathological features in asthma models. However, extending these experimental findings to clinical applications is difficult. Several measures can be adopted to promote clinical application of EGFR inhibitors. This review focuses on the role of EGFR in the pathogenesis of asthma and the development of a potentially novel therapeutic target for asthma.

Keywords: Asthma; Epidermal growth factor receptor; Epithelial cell barrier; Inflammation; Targeted therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Asthma* / metabolism
ErbB Receptors*
Humans
Signal Transduction

Substances

ErbB Receptors
EGFR protein, human